Data / Drug companies / Eugia US LLC
Eugia US LLC: 284 products in the FDA NDC directory, labeler code 55150
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Eugia US LLC (labeler code 55150) lists 284 products in the FDA National Drug Code Directory, covering 117 finished drugs by generic name. By type: 284 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on January 27, 2026.
The request: Watch Eugia US LLC (FDA labeler code 55150): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 55150
- Products in commercial distribution
- 284
- Packages
- 318
- Finished drugs by generic name
- 117
- Prescription products
- 284
- Over the counter products
- 0
- Controlled substance products
- Schedule III 8
- Flagged as original packager
- 275 of 275 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- January 23, 2012
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 280 | 98.6% |
| New drug applications (NDA) | 4 | 1.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 284 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 159 | 56% |
| Injection, powder, lyophilized, for solution | 47 | 16.5% |
| Injection | 40 | 14.1% |
| Injection, powder, for solution | 23 | 8.1% |
| Injection, suspension | 6 | 2.1% |
| Kit | 4 | 1.4% |
| Injection, solution, concentrate | 3 | 1.1% |
| Powder, for solution | 1 | 0.4% |
| Solution | 1 | 0.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Mesna | 55150-520 | Injection, solution | Generic drugs (ANDA) | January 27, 2026 |
| Methotrexate | 55150-513 | Injection, solution | Generic drugs (ANDA) | September 11, 2024 |
| Methotrexate | 55150-512 | Injection, solution | Generic drugs (ANDA) | September 11, 2024 |
| Methotrexate | 55150-511 | Injection, solution | Generic drugs (ANDA) | September 11, 2024 |
| Methotrexate | 55150-510 | Injection, solution | Generic drugs (ANDA) | September 11, 2024 |
| Busulfan | 55150-395 | Injection, solution | Generic drugs (ANDA) | June 25, 2024 |
| Testosterone enanthate | 55150-336 | Injection, solution | Generic drugs (ANDA) | February 28, 2024 |
| Gentamicin | 55150-403 | Injection, solution | Generic drugs (ANDA) | January 8, 2024 |
| Gentamicin | 55150-402 | Injection, solution | Generic drugs (ANDA) | January 8, 2024 |
| Gentamicin | 55150-401 | Injection, solution | Generic drugs (ANDA) | January 8, 2024 |
| Posaconazole | 55150-388 | Injection | Generic drugs (ANDA) | December 26, 2023 |
| Neostigmine methylsulfate | 55150-349 | Injection | Generic drugs (ANDA) | November 2, 2023 |
| Neostigmine methylsulfate | 55150-348 | Injection | Generic drugs (ANDA) | November 2, 2023 |
| Mitomycin | 55150-452 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 30, 2023 |
| Mitomycin | 55150-451 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 30, 2023 |
| Mitomycin | 55150-450 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 30, 2023 |
| Testosterone Cypionate | 55150-278 | Injection, solution | Generic drugs (ANDA) | October 20, 2023 |
| Testosterone Cypionate | 55150-277 | Injection, solution | Generic drugs (ANDA) | October 20, 2023 |
| Testosterone Cypionate | 55150-276 | Injection, solution | Generic drugs (ANDA) | October 20, 2023 |
| Succinylcholine chloride | 55150-315 | Injection, solution | Generic drugs (ANDA) | October 16, 2023 |
| Piperacillin and Tazobactam | 55150-474 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 12, 2023 |
| Piperacillin and Tazobactam | 55150-473 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 12, 2023 |
| Icatibant | 55150-351 | Injection, solution | Generic drugs (ANDA) | August 14, 2023 |
| Vancomycin hydrochloride | 55150-472 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 4, 2023 |
| Vancomycin hydrochloride | 55150-471 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 4, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.